Movement Disorder Specialists’ Determination of Eligibility for Device Aided Treatment in Advanced Parkinson’s Disease: Results from the OBSERVE-PD Study (P5.069)

Objective: To characterize the clinical and non-clinical features of Parkinson’s disease (PD) patients considered to be eligible or ineligible for device-aided treatment options by movement disorder specialists. Background: OBSERVE-PD was a cross-sectional, observational study conducted at 128 movement disorder centers in 18 countries. A previous analysis reported that physicians judged 51% of the PD patients in participating movement disorder centers as ‘advanced’. Design/Methods: This is a post hoc analysis of the clinical and non-clinical characteristics of ‘advanced’ PD patients judged to be eligible or ineligible for device-aided treatment by the treating physician. Device-aided treatments included levodopa-carbidopa intestinal gel, apomorphine subcutaneous infusion, and neurosurgical treatments. Patient characteristics were analyzed using descriptive statistics. Results: Sixty-six percent (n=876) of advanced PD patients were considered eligible for device-aided treatment options. Device-aided treatment -eligible patients were on average 66.0 years old with a mean PD duration of 12.2 years. Device-aided treatment -ineligible patients had a mean age and PD duration of 70.6 and 8.6 years, respectively. The primary reasons given for lack of device-aided treatment use were the patient needing more time to make a decision (43%) and patient refusal (28%). Notably, no patients stated cost or lack of reimbursement as reasons for lack of use. Of the advanced PD patients judged as device-aided treatment - eligible, 44% had ongoing device-aided treatment, 19% had decided to begin device-aided treatment during the study visit. Conclusions: This analysis shows a trend for advanced PD patients judged device-aided treatment -ineligible to be generally older individuals, with shorter disease duration, than device-aided treatment -eligible PD patients, however, direct statistical comparisons were not performed. The primary reasons given for device-aided treatment-ineligibility were related to patient refusal/patient needing additional time to decide. Study Supported by: AbbVie Inc. Disclosure: Dr. Fasano has nothing to disclose. Dr. Seppi has nothing to disclose. Dr. Fung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NSW Health, AbbVie Inc., Allergan, Hospira, Ipsen, Lundbeck, Merz, Mundi Pharma and UCB. Dr. Fung has received research support from National Health and Medical Research Council of Australia and AbbVie Inc. Dr. Parra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Parra holds stock and/or stock options in AbbVie Inc. Dr. Bergmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Bergmann holds stock and/or stock options in AbbVie Inc. Dr. Sail has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Sail holds stock and/or stock options in AbbVie Inc. Dr. Jalundhwala has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie (Employment). Dr. Jalundhwala holds stock and/or stock options in AbbVie, which sponsored research in which Dr. Jalundhwala was involved as an investigator. Dr. Onuk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Onuk holds stock and/or stock options in AbbVie Inc.